A Phase 2 interventional study of abiraterone acetate with Methylprednisolone in Metastatic Prostate Cancer, sponsored by Sun Pharmaceutical Industries Limited. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 79th largest by enrollment, is one of 7 that started in 2016, is one of 59 in phase 2, and was the 54th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Sun Pharmaceutical Industries Limited has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid). Patients will have successfully completed an 84-day treatment with abiraterone acetate in a previous trial. Results from the final visit of the previous study will be used to determine patient's eligibility for this study. Patients in this study will be eligible to receive open-label YONSA with methylprednisolone for up to 12 months. Pharmacodynamic parameters of serum testosterone and PSA levels will be monitored. Disease progression will be assessed by PCWG2 criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Drug: abiraterone acetate with Methylprednisolone
Drug pages: Abiraterone Acetate · Methylprednisolone
YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Also known as: YONSA
Number of Subjects With Adverse Events
Adverse events
Time frame: one year
Proportion of Subjects With Disease Progression
Number of participants who had disease progression
Time frame: one year
Testosterone Levels
Change in serum testosterone levels from baseline
Time frame: Baseline and 360 days
Prostate Specific Antigen Levels
Change in serum testosterone levels after one year of treatment against baseline
Time frame: One year
Testosterone Complete Suppression
Proportion of subjects with complete suppression of testosterone levels
Time frame: 360 days
Percentage of Subjects With Prostate Specific Antigen - 50 Response
A decrease of ≥50% reduction from baseline of the study CHL-AA-201
Time frame: 360 days
A total of 20 subjects were enrolled in the study. Of these, 9 subjects were previously treated with YONSA and 11 subjects were previously treated with Zytiga in CHL-AA-201. Twelve (60.0%) subjects completed the study
| Milestone | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Started | 9 | 11 |
| Completed | 4 | 8 |
| Not completed | 5 | 3 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Progressive disease | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Adverse events
| Participants | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Number of Subjects With Adverse Events | 8 | 9 |
Number of participants who had disease progression
| Participants | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Proportion of Subjects With Disease Progression | 1 | 3 |
Change in serum testosterone levels from baseline
| ng/dL | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Testosterone Levels | -6.24 ± 2.02 | -5.87 ± 3.64 |
Change in serum testosterone levels after one year of treatment against baseline
| ng/dL | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Prostate Specific Antigen Levels | -60.12 ± 115.63 | -112.76 ± 239.85 |
Proportion of subjects with complete suppression of testosterone levels
| percentage of subjects | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Testosterone Complete Suppression | 100 | 87.5 |
A decrease of ≥50% reduction from baseline of the study CHL-AA-201
| percentage of number of subjects | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Percentage of Subjects With Prostate Specific Antigen - 50 Response | 60.0 | 55.6 |
Collected over One year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Preceding Treatment - Yonsa | 2/9 (22.2%) | 3/9 (33.3%) | 8/9 (88.9%) |
| Preceding Treatment - Zytiga | 0/11 (0%) | 1/11 (9.1%) | 9/11 (81.8%) |
| Event | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| Septic shockInfections and infestations | 1/9 | 0/11 |
| Head injuryInjury, poisoning and procedural complications | 1/9 | 0/11 |
| AbasiaGeneral disorders | 1/9 | 0/11 |
| AstheniaGeneral disorders | 1/9 | 0/11 |
| DehydrationMetabolism and nutrition disorders | 1/9 | 0/11 |
| Non-cardiac chest painGeneral disorders | 1/9 | 0/11 |
| Right leg cellulitisInfections and infestations | 0/9 | 1/11 |
| Event | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga |
|---|---|---|
| BronchitisInfections and infestations | 0/9 | 2/11 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/9 | 0/11 |
| NauseaGastrointestinal disorders | 1/9 | 0/11 |
| VomitingGastrointestinal disorders | 1/9 | 0/11 |
| AbasiaGeneral disorders | 1/9 | 0/11 |
| AstheniaGeneral disorders | 1/9 | 0/11 |
| Face oedemaGeneral disorders | 1/9 | 0/11 |
| FatigueGeneral disorders | 1/9 | 1/11 |
| MassGeneral disorders | 1/9 | 0/11 |
| NoduleGeneral disorders | 1/9 | 0/11 |
| Age, Customized(Participants) | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga | Total |
|---|---|---|---|
| <75 years | 4 | 5 | 9 |
| ≥75 years | 5 | 6 | 11 |
| Sex/Gender, Customized(Participants) | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga | Total |
|---|---|---|---|
| Male | 9 | 11 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Preceding Treatment - Yonsa | Preceding Treatment - Zytiga | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 7 | 11 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We do not plan to make individual participant data available
Ran from Nov 2016 to primary completion in Mar 2018, 16 months.
Results were first posted in Jul 2019, 1 year 4 months after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 16 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abiraterone Acetate · Methylprednisolone
Sun Pharmaceutical Industries Limited →